首页> 外文期刊>Journal of Biomedical Science and Engineering >Ezetimibe Completely Replaced LDL-Apheresis for the Treatment of Familial Hypercholesterolemia and Coronary Artery Disease after CABG—A Case Report
【24h】

Ezetimibe Completely Replaced LDL-Apheresis for the Treatment of Familial Hypercholesterolemia and Coronary Artery Disease after CABG—A Case Report

机译:依泽替米贝完全替代LDL-单采血液透析治疗家族性高胆固醇血症和冠状动脉疾病后CABG —病例报告

获取原文
       

摘要

Intensive treatment of hyperlipidemia is an important factor in the prevention of cardiovascular disease. Among several therapies, statins are well recognized as playing a central role, although low density lipoprotein bound cholesterol-apheresis can be used to treat very severe cases of familial hypercholesterolemia. However, statins are not always effective on their own and, recently, ezetimibe has emerged as a unique anti- hypercholesterolemic drug that acts as a cholesterol transporter inhibitor; its role is only partially understood. I experienced rare case that appeared to benefit from ezetimibe therapy, and report them as they help increase our knowledge of this novel drug.
机译:高脂血症的强化治疗是预防心血管疾病的重要因素。在几种疗法中,尽管低密度脂蛋白结合胆固醇可用于治疗非常严重的家族性高胆固醇血症病例,但他汀类药物已被公认为起核心作用。但是,他汀类药物本身并不总是有效的,最近,依泽替米贝已成为一种独特的抗高胆固醇血症药物,可作为胆固醇转运抑制剂。其作用只是部分理解。我遇到了罕见的病例,似乎从依泽替米贝疗法中受益,并报告了它们,因为它们有助于增加我们对该新药的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号